Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Tiragolumab vs Durvalumab in Stage III NSCLC
NCT04513925Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2020
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 26
01
Overview
A Phase 3 trial of atezolizumab, tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Aug 2020; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04513925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513925.